Cardiovascular risk in patients with treated familial hypercholesterolaemia and patients with severe hypertriglyceridaemia

Simpson H.C.R. , Mann J.I. , Meade T.W. , Chakrabarti E. , Stirling Y. , Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet 1983; i: 786–90

Stout R.W. , Bierman E.L. , Brunzell J.D. Atherosclerosis and disorders of lipid metabolism in diabetes. In: Vallance-Owen J. , ed. Diabetes, its physiological and biochemical basis. Lancaster: MTP Press, 1975: 125–69

Fuller J.H. , Keen H. , Jarrett R.J. Haemostatic variables associated with diabetes and its complications. Br Med J 1979; ii: 964–6

Aimer L-O , Kjellstrom T. The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridaemia. Atherosclerosis 1986; 61: 81–5

Mikhailidis D.P. , Barradas M.A. , Maris A. , Jeremy J.Y. , Dandona P. Fibrinogen mediated activation of platelet aggregation and thromboxane A₂ release: pathological implications in vascular disease. J Clin Pathol 1986; 38: 1166–71

Carlson T.H. , Wentland S.H. , Leonard B.D. , Ruder M.A. , Reeve E.B. Effects of prostaglandin E, analogs, fatty acids and indomethacin on fibrinogen level. Am J Physiol 1978; 235: H223–30

Mikhailidis D.P. , Kirtland S.J. , Barradas M.A. , Mahadevia S. , Dandona P. The effect of dihomogammalinolenic acid on platelet aggregation and prostaglandin release, erythrocyte membrane fatty acids and serum lipids: evidence for defects in PGE, synthesis and ▲⁵-desturase activity in insulin-dependent diabetics. Diabetes Res 1986; 3: 7–12